YSP Southeast Asia Holding Bhd Cash Flow Conversion Efficiency

Latest as of June 2026: 0.066x

YSP Southeast Asia Holding Bhd cash flow conversion efficiency. Based on the latest financial reports, YSP Southeast Asia Holding Bhd (7178) has a cash flow conversion efficiency ratio of 0.066x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (RM28.53 Million ≈ $7.16 Million USD) by net assets (RM432.22 Million ≈ $108.52 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of YSP Southeast Asia Holding Bhd (2012–2025)

Cash flow conversion efficiency of YSP Southeast Asia Holding Bhd from 2012 to 2025. This chart illustrates how YSP Southeast Asia Holding Bhd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of YSP Southeast Asia Holding Bhd for real-time trading data and today's change.

YSP Southeast Asia Holding Bhd Cash Flow Conversion Ratio Explained

YSP Southeast Asia Holding Bhd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

YSP Southeast Asia Holding Bhd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of YSP Southeast Asia Holding Bhd ranked by their cash flow conversion efficiency. Also see 7178 market cap overview for the company's overall valuation and market capitalisation.

Company Cash Flow Conversion Efficiency
SLP Resources Bhd
KLSE:7248
0.081x
Rani Therapeutics Holdings Inc
NASDAQ:RANI
-0.188x
DENARIUS METALS CORP.
F:T7C0
-0.039x
Creepy Jar SA
WAR:CRJ
0.241x
Shanghai Lingang Holdings Co Ltd B
SHG:900928
-0.013x
P.A. Resources Bhd
KLSE:7225
-0.020x
Hainan Airlines Co Ltd B
SHG:900945
0.547x
Conexeu Sciences Inc. Common Stock
NASDAQ:CNXU
-0.251x

Annual Cash Flow Conversion Efficiency for YSP Southeast Asia Holding Bhd (2012–2025)

The table below shows the annual cash flow conversion efficiency of YSP Southeast Asia Holding Bhd from 2012 to 2025. Review YSP Southeast Asia Holding Bhd free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 RM425.70 Million
≈ $106.88 Million
RM54.46 Million
≈ $13.67 Million
0.128x +5.26%
2024-12-31 RM409.02 Million
≈ $102.69 Million
RM49.71 Million
≈ $12.48 Million
0.122x +32.17%
2023-12-31 RM395.06 Million
≈ $99.19 Million
RM36.33 Million
≈ $9.12 Million
0.092x -29.17%
2022-12-31 RM372.16 Million
≈ $93.44 Million
RM48.31 Million
≈ $12.13 Million
0.130x -29.31%
2021-12-31 RM346.50 Million
≈ $87.00 Million
RM63.63 Million
≈ $15.98 Million
0.184x +593.57%
2020-12-31 RM342.60 Million
≈ $86.01 Million
RM9.07 Million
≈ $2.28 Million
0.026x -73.32%
2019-12-31 RM328.19 Million
≈ $82.40 Million
RM32.58 Million
≈ $8.18 Million
0.099x +54.77%
2018-12-31 RM315.05 Million
≈ $79.10 Million
RM20.20 Million
≈ $5.07 Million
0.064x -32.73%
2017-12-31 RM289.51 Million
≈ $72.69 Million
RM27.60 Million
≈ $6.93 Million
0.095x -37.56%
2016-12-31 RM274.41 Million
≈ $68.89 Million
RM41.90 Million
≈ $10.52 Million
0.153x +49.30%
2015-12-31 RM264.00 Million
≈ $66.28 Million
RM27.00 Million
≈ $6.78 Million
0.102x +74.59%
2014-12-31 RM239.00 Million
≈ $60.01 Million
RM14.00 Million
≈ $3.51 Million
0.059x -55.09%
2013-12-31 RM230.00 Million
≈ $57.75 Million
RM30.00 Million
≈ $7.53 Million
0.130x +71.10%
2012-12-31 RM223.00 Million
≈ $55.99 Million
RM17.00 Million
≈ $4.27 Million
0.076x --

About YSP Southeast Asia Holding Bhd

KLSE:7178 Malaysia Drug Manufacturers - Specialty & Generic
Market Cap
$68.02 Million
RM270.92 Million MYR
Market Cap Rank
#20513 Global
#401 in Malaysia
Share Price
RM1.91
Change (1 day)
-0.52%
52-Week Range
RM1.91 - RM2.20
All Time High
RM2.95
About

Y.S.P. Southeast Asia Holding Berhad, together with its subsidiaries, engages in the manufacturing and trading of generic drugs in Malaysia, Singapore, Vietnam, Philippines, Cambodia, Myanmar, Brunei, Indonesia, Thailand, Africa, and internationally. It operates through three segments: Manufacturing, Trading, and Investment Holding. The company manufactures, sells, imports, exports, trades in, an… Read more